Otros idiomas Iconovo AB

Acciones

ICO

SE0010868943

Mercado cerrado - Nasdaq Stockholm Otros sitios de cotización 17:13:49 06/05/2024			Varia. Cinco días.	Varia. 1 de enero.
7,98 ^SEK	-0,25 %		+2,84 %	-30,91 %

06/05	La sueca Iconovo recibirá la patente china del inhalador ICOres	MT
06/05	Iconovo AB (publ) recibe la protección de patente para Icores en China	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Sweden's Iconovo to Receive Chinese Patent for ICOres Inhaler	06/05
Iconovo receives patent protection for ICOres® in China	06/05
Iconovo AB Receives Patent Protection for Icores in China	06/05
Iconovo Q1 - Solid quarter with a near-term catalyst on the horizon	26/04
Iconovo AB Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04
Iconovo to present positive data from a feasibility study on Nanofitins® in ICOone®	11/03
Iconovo AB and Affilogic to Present Positive Data from a Feasibility Study on Nanofitins in ICOone	11/03
Iconovo receives grant of SEK 680,000 from Innowwide for market efforts in South Korea	05/03
Iconovo Q4 - Aligned with our expectations and a directed issue announcement	19/02
Iconovo AB Reports Earnings Results for the Full Year Ended December 31, 2023	15/02
Iconovo AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15/02
Iconovo carries out a directed share issue of SEK 33.3 million, partly subject to subsequent approval by the Extraordinary General Meeting, and brings forward the publication of the year-end report	15/02
Iconovo signs additional contract with Kiox Pharma for the development of a new inhalable treatment for interstitial lung disease	07/02
Iconovo AB Signs Additional Contract with Kiox Pharma for the Development of A New Inhalable Treatment for Interstitial Lung Disease	07/02
Iconovo launches improved versions of nasal ICOone® inhalers	06/02
Iconovo AB Launches Improved Versions of Nasal ICOone Inhalers	06/02
Iconovo receives order from Top-10 Pharma company for evaluation of multi-dose inhaler	01/02
Iconovo Receives Order from Top-10 Pharma Company for Evaluation of Multi-Dose Inhaler	01/02
Iconovo recruits Gary Pitcairn (PhD) as Senior Scientific Advisor	08/01
Redeye Initiates Coverage of Iconovo	06/12

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Iconovo AB

Acciones

ICO

SE0010868943

Otros idiomas

Filtros